RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma

BACKGROUND: Neoadjuvant chemotherapy – often using docetaxel in various combinatorial regimens – is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxel’s effects on ESCC. Ribophorin II (RPN2) silencing,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurashige, J, Watanabe, M, Iwatsuki, M, Kinoshita, K, Saito, S, Nagai, Y, Ishimoto, T, Baba, Y, Mimori, K, Baba, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494434/
https://www.ncbi.nlm.nih.gov/pubmed/22955852
http://dx.doi.org/10.1038/bjc.2012.396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494434/
https://www.ncbi.nlm.nih.gov/pubmed/22955852
http://dx.doi.org/10.1038/bjc.2012.396

Ejemplares similares